An Italian cannabis referendum could potentially lead to the decriminalisation of psychotropic substance cultivation, such as cannabis and mushrooms, for personal use if successful.
The first patient has received a dose of psilocybin in the world’s first trial investigating psilocybin as a treatment for a rare and debilitating headache disorder...
A new partnership between a Danish and a British startup will lead the way for advancing patient access to medical psychedelics in Europe.
Little Green Pharma has been granted a licence to supply psilocybin from the Western Australia Government Department of Health.
The first-ever authorised export of GMP-compliant natural psilocybin into the US has been completed.
Tryp Therapeutics has completed psychotherapy training for its upcoming Phase 2a psilocybin clinical trial.
Braxia Scientific will be carrying out a landmark clinical trial investigating multiple-dose psilocybin for treatment-resistant depression.
A psychedelic medicine startup will be developing a transdermal patch for sustained delivery of psilocin.
Diamond Therapeutics has received approval from Health Canada to carry out a clinical trial for the treatment of mental health conditions with low-dose psilocybin.
Beckley Psytech has raised £58m from investors and supporters in an oversubscribed Series B financing round.